726 related articles for article (PubMed ID: 25887482)
21. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
[TBL] [Abstract][Full Text] [Related]
22. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.
Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
Front Immunol; 2021; 12():749459. PubMed ID: 34603338
[TBL] [Abstract][Full Text] [Related]
23. Histological Features and Tissue Microarray Taxonomy of Nigerian Breast Cancer Reveal Predominance of the High-Grade Triple-Negative Phenotype.
Titloye NA; Foster A; Omoniyi-Esan GO; Komolafe AO; Daramola AO; Adeoye OA; Adisa AO; Manoharan A; Pathak D; D'Cruz MN; Alizadeh Y; Lewis PD; Shaaban AM
Pathobiology; 2016; 83(1):24-32. PubMed ID: 26730581
[TBL] [Abstract][Full Text] [Related]
24. Basal markers and prognosis in luminal breast cancer.
Engstrøm MJ; Valla M; Bofin AM
Breast Cancer Res Treat; 2017 Jun; 163(2):207-217. PubMed ID: 28258354
[TBL] [Abstract][Full Text] [Related]
25. Differences in molecular features of triple-negative breast cancers based on the age at diagnosis.
Gulbahce HE; Bernard PS; Weltzien EK; Factor RE; Kushi LH; Caan BJ; Sweeney C
Cancer; 2018 Dec; 124(24):4676-4684. PubMed ID: 30311638
[TBL] [Abstract][Full Text] [Related]
26. Clinical and molecular characteristics of bladder urothelial carcinoma subtypes.
Li Y; Yang K; Li K; Liu H; Zhao S; Jiao M; Fu X
J Cell Biochem; 2019 Jun; 120(6):9956-9963. PubMed ID: 30548659
[TBL] [Abstract][Full Text] [Related]
27. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
[TBL] [Abstract][Full Text] [Related]
28. Salivary gland-like tumors of the breast express basal-type immunohistochemical markers.
Reyes C; Jorda M; Gomez-Fernández C
Appl Immunohistochem Mol Morphol; 2013 Jul; 21(4):283-6. PubMed ID: 22935826
[TBL] [Abstract][Full Text] [Related]
29. Claudin-3 and claudin-4: distinct prognostic significance in triple-negative and luminal breast cancer.
Kolokytha P; Yiannou P; Keramopoulos D; Kolokythas A; Nonni A; Patsouris E; Pavlakis K
Appl Immunohistochem Mol Morphol; 2014; 22(2):125-31. PubMed ID: 23702644
[TBL] [Abstract][Full Text] [Related]
30. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
31. FOXA2 mRNA expression is associated with relapse in patients with Triple-Negative/Basal-like breast carcinoma.
Perez-Balaguer A; Ortiz-Martínez F; García-Martínez A; Pomares-Navarro C; Lerma E; Peiró G
Breast Cancer Res Treat; 2015 Sep; 153(2):465-74. PubMed ID: 26298189
[TBL] [Abstract][Full Text] [Related]
32. Gene-expression signature functional annotation of breast cancer tumours in function of age.
Jézéquel P; Sharif Z; Lasla H; Gouraud W; Guérin-Charbonnel C; Campion L; Chrétien S; Campone M
BMC Med Genomics; 2015 Nov; 8():80. PubMed ID: 26597277
[TBL] [Abstract][Full Text] [Related]
33. Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.
Kim HK; Park KH; Kim Y; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Lee JE; Ahn JS; Im YH; Yu JH; Park YH
Cancer Res Treat; 2019 Apr; 51(2):737-747. PubMed ID: 30189722
[TBL] [Abstract][Full Text] [Related]
34. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
[TBL] [Abstract][Full Text] [Related]
35. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
36. Molecular analyses of triple-negative breast cancer in the young and elderly.
Aine M; Boyaci C; Hartman J; Häkkinen J; Mitra S; Campos AB; Nimeus E; Ehinger A; Vallon-Christersson J; Borg Å; Staaf J
Breast Cancer Res; 2021 Feb; 23(1):20. PubMed ID: 33568222
[TBL] [Abstract][Full Text] [Related]
37. Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival.
Michaelidou K; Ardavanis A; Scorilas A
Breast Cancer Res Treat; 2015 Jul; 152(2):323-36. PubMed ID: 26099606
[TBL] [Abstract][Full Text] [Related]
38. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer.
Ochoa AE; Choi W; Su X; Siefker-Radtke A; Czerniak B; Dinney C; McConkey DJ
Oncotarget; 2016 Dec; 7(49):80164-80174. PubMed ID: 27845906
[TBL] [Abstract][Full Text] [Related]
39. Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers.
Yan M; Shield-Artin K; Byrne D; Deb S; Waddell N; ; Haviv I; Fox SB
BMC Cancer; 2015 Jul; 15():506. PubMed ID: 26152113
[TBL] [Abstract][Full Text] [Related]
40. Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors.
Sizemore ST; Sizemore GM; Booth CN; Thompson CL; Silverman P; Bebek G; Abdul-Karim FW; Avril S; Keri RA
Breast Cancer Res Treat; 2014 Jul; 146(1):25-40. PubMed ID: 24847890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]